Skip to content

卡迪根

US · KARD #3042 按市值排名 上市于 2026
13.03 -0.85 -6.12%
实时 - 追踪5344个代码 - 心跳于329秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 2.05 处于历史正常水平 第52百分位
5年平均 -1.54 · 在Biotechnology中排名第227/514
市盈率 -4.37 高于历史水平 第95百分位
5年平均 -6.80 · 前瞻 -3.49
市销率 --
5年平均 0.00

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
卡迪根 (KARD) 1.22B -4.22 1.98 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★★ 合理价值23.69 经济护城河None 不确定性Very High

当前股价低于晨星合理价值估算81.8%。

合理价值

Kardigan Inc earns a 5-star quantitative star rating, reflecting our opinion that this share class offers a compelling opportunity for investors. The stock currently trades at a 43% discount to our quantitative fair value estimate of $23.69 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 2.2 falls in the bottom 20% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.

Alternatively, the company's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, lies in the bottom 30% compared with global peers. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.

经济护城河

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

卡迪根 讨论区 0 条评论

发表评论